Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Share and Global Trend By Product (Steroids, Antidepressants, Anti-Seizure Medicines, Narcotics), By Distribution Channel (Hospital Pharmacy, Retails Pharmacy, Online Pharmacy) and Regional Forecast, 2024-2032

In October 2018, IDIBELL-Bellvitge Biomedical Research Institute examined the safety and efficacy of a new molecule against chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of many commonly used chemotherapeutic agents, which includes vinca alkaloids, platinum drugs, epothilones, taxanes, and also newer agents such as bortezomib and lenolidamide.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a painful dysfunction of the somatosensory nervous system. Chemotherapy-Induced Peripheral Neuropathy (CIPN) affects an estimated 68.0% of patients undergoing chemotherapy within the first month and affects 30% of patients on a chronic basis.

Increasing adoption of chemotherapy is one of the prime factor for increasing prevalence of peripheral neuropathy. Moreover, lack of proper guidelines regarding chemotherapy elevates the chances of additional incidence of peripheral neuropathy. Such factors are expected to drive the growth of the chemotherapy induced peripheral neuropathy market during the forecast period.

Lack of awareness regarding symptoms of chemotherapy induced peripheral neuropathy is expected to hamper the growth of the chemotherapy induced peripheral neuropathy treatment market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global chemotherapy induced peripheral neuropathy treatment market are Eurofins Advinus, WEX Phamaceuticals Inc., Asahi Kasei Corporation., MediciNova, Inc., Solasia Pharma K.K., ESTEVE, ChromaDex, Inc., Apollo Endosurgery, Inc., F. Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA and other prominent players.

SEGMENTATION 

Among the segmentation, steroids are projected to hold a considerable share of the global chemotherapy induced peripheral neuropathy treatment market owing greater efficacy and high adoption of the steroidal drugs across each geographical region.

Key Insights

• The regulatory scenario for key countries


• New product introductions by key players


• Pipeline analysis


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

On the basis of region, the global chemotherapy induced peripheral neuropathy treatment market is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among the region, North America is expected to dominate global chemotherapy induced peripheral neuropathy treatment market during the forecast period. Increasing prevalence of cancer is leading to rise in the demand for the chemotherapy treatment by the patients in the North America region. This is anticipated to drive the growth of the chemotherapy induced peripheral neuropathy treatment in North America. According to Centre for Disease Control and Prevention (CDC), in 2015, an estimated 1,633,390 new cases of cancer were reported, and an estimated 595,919 people died of cancer in the United States. Europe and Asia Pacific are anticipated to grow at a significant CAGR in the forecast period of 2019-2026.

Key Industry Developments

• In May 2015, WEX Phamaceuticals Inc., presented preclinical results of Tetrodotoxin in the treatment of chemotherapy induced peripheral neuropathy at 34^th annual meeting of American Pain Society.
• In November 2017, the association of PledPharma and Solasia agreed upon strategic partnership to develop and market PledOx, potential drug for the preventive treatment of chemotherapy induced peripheral neuropathy in Asia market.